Fujisawa Enters Research Agreement With Pharmagenesis

Fujisawa Pharmaceutical Co., Ltd., has executed a collaborative research agreement with Pharmagenesis, Inc., with regard to triptolide derivatives, novel and potent immunosuppressants created by Pharmagenesis. The agreement also gives Fujisawa an option to acquire the exclusive and worldwide (certain territories are under negotiation) development and marketing rights to Pharmagenesis’ compounds in the therapeutic areas of Read more about Fujisawa Enters Research Agreement With Pharmagenesis[…]

eXegenics And Innovative Drug Delivery Systems To Merge

eXegenics Inc. Innovative Drug Delivery Systems, Inc. (IDDS) have signed a definitive merger agreement. Mark C. Rogers, M.D., currently Chairman and CEO of IDDS, will be named Executive Chairman of the combined company and Dr. Ronald L. Goode, Ph.D., currently eXegenics’ President and CEO, will continue as President and CEO. “The merger of eXegenics and Read more about eXegenics And Innovative Drug Delivery Systems To Merge[…]

AstraZeneca Completes NDA For Iressa

AstraZeneca has announced that the final documents of the NDA, for IRESSA (ZD1839) have been submitted to the U.S. FDA completing the rolling submission for the drug that began last summer. All clinical data including safety and efficacy information was provided to the agency in December. IRESSA is being considered as a monotherapy agent for Read more about AstraZeneca Completes NDA For Iressa[…]

Amgen Receives EC Approval

Amgen has received EC approval for Aranesp and Neulasta as oncology therapies. The European Commission (EC) has approved both darbepoetin alfa (Aranesp/Nespo for the treatment of anaemia in adult cancer patients with solid tumours (non- haematological malignancies) receiving chemotherapy, and pegfilgrastim (Neulasta/Neupopeg) for the reduction in the duration of neutropenia and the incidence of febrile Read more about Amgen Receives EC Approval[…]

Transmolecular Awarded Phase II Sbir Grant

TransMolecular, Inc. has received a Phase II Small Business Innovation Research (SBIR) grant to discover and develop pharmaceutical alternatives for treating neuropathic pain. The grant is worth approximately $760,000 over the next two years. “Neuropathic or chronic pain represents an underserved medical need. Ion channels have played an important part in the development of many Read more about Transmolecular Awarded Phase II Sbir Grant[…]

Wright Medical, Lifecell Agree Development Collaboration

Wright Medical Group, Inc has entered into an exclusive agreement with LifeCell Corporation for the development and supply of a product based on LifeCell’s proprietary tissue matrix technology for orthopaedic applications. Under the terms of the agreement, the tissue matrix product will be used in conjunction with Wright Medical’s comprehensive bio- orthopaedic portfolio of products. Read more about Wright Medical, Lifecell Agree Development Collaboration[…]

Prodigene Announces Milestone In Nih Collaboration

ProdiGene, Inc. announced at the Keystone Symposia, that it successfully expressed a sub unit vaccine in maize that is expected to produce an immune response to simian immunodeficiency virus (SIV), the primate equivalent to HIV.The research is funded by an Innovation Grant program from the NIH Institute of Allergy and Infectious Disease’s Office of AIDS Read more about Prodigene Announces Milestone In Nih Collaboration[…]

Berna And Iomai Announce Collaboration

Berna Biotech Ltd. and Iomai Corporation have announced a collaboration for the development of vaccines for administration using a skin patch. The collaboration will pool Berna’s expertise in the development of vaccines and novel adjuvants with Iomai’s expertise in skin delivery using its proprietary patch technology. Needle-free delivery has become a global priority because of Read more about Berna And Iomai Announce Collaboration[…]

Bioenvision Completes Acquisition Of Pathagon

Bioenvision has closed its acquisition of Pathagon, a privately held company focused on the development of novel anti-infective products and technologies. With the acquisition, Bioenvision adds to its portfolio the rights to two FDA approved and marketed anti-infective technologies, OLIGON (TM) and methylene blue. Dr. Chris Wood MD, Bioenvision’s President & CEO, commented, “we are Read more about Bioenvision Completes Acquisition Of Pathagon[…]

Approvable Letter Received For Uroxatral

SkyePharma PLC and Sanofi-Synthelabo have received an “approvable letter” from the US FDA for UroXatral (once-daily formulation of alfuzosin) for the symptomatic treatment of benign prostatic hyperplasia. The formulation utilizes SkyePharma’s proprietary oral drug delivery technology, GEOMATRIX. The New Drug Application for UroXatral was submitted in December 2000 in the United States. Michael Ashton, SkyePharma’s Read more about Approvable Letter Received For Uroxatral[…]